BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 29790593)

  • 1. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series.
    Le Sage S; David M; Dubois J; Powell J; McCuaig CC; Théorêt Y; Kleiber N
    Pediatr Dermatol; 2018 Jul; 35(4):472-477. PubMed ID: 29790593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of superficial vascular anomalies with topical sirolimus: A multicenter case series.
    Dodds M; Tollefson M; Castelo-Soccio L; Garzon MC; Hogeling M; Hook K; Boull C; Maguiness S
    Pediatr Dermatol; 2020 Mar; 37(2):272-277. PubMed ID: 31957126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical sirolimus for the treatment of cutaneous manifestations of vascular anomalies: A case series.
    Badia P; Ricci K; Gurria JP; Dasgupta R; Patel M; Hammill A
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28088. PubMed ID: 31930696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical rapamycin and microcystic lymphatic malformations.
    Gu Y; Sebaratnam DF
    J Am Acad Dermatol; 2024 Jan; 90(1):e29-e30. PubMed ID: 37717734
    [No Abstract]   [Full Text] [Related]  

  • 5. Sirolimus in the Treatment of Vascular Anomalies.
    Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
    Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
    [No Abstract]   [Full Text] [Related]  

  • 6. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
    Maruani A; Tavernier E; Boccara O; Mazereeuw-Hautier J; Leducq S; Bessis D; Guibaud L; Vabres P; Carmignac V; Mallet S; Barbarot S; Chiaverini C; Droitcourt C; Bursztejn AC; Lengellé C; Woillard JB; Herbreteau D; Le Touze A; Joly A; Léauté-Labrèze C; Powell J; Bourgoin H; Gissot V; Giraudeau B; Morel B
    JAMA Dermatol; 2021 Nov; 157(11):1289-1298. PubMed ID: 34524406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of topical rapamycin in the treatment of superficial lymphatic malformations.
    García-Montero P; Del Boz J; Baselga-Torres E; Azaña-Defez JM; Alcaraz-Vera M; Tercedor-Sánchez J; Noguera-Morel L; Vera-Casaño Á
    J Am Acad Dermatol; 2019 Feb; 80(2):508-515. PubMed ID: 30296533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus for the treatment of complicated vascular anomalies in children.
    Hammill AM; Wentzel M; Gupta A; Nelson S; Lucky A; Elluru R; Dasgupta R; Azizkhan RG; Adams DM
    Pediatr Blood Cancer; 2011 Dec; 57(6):1018-24. PubMed ID: 21445948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review.
    Wiegand S; Wichmann G; Dietz A
    Lymphat Res Biol; 2018 Aug; 16(4):330-339. PubMed ID: 29924669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
    Leducq S; Caille A; Barbarot S; Bénéton N; Bessis D; Boccara O; Bursztejn AC; Chiaverini C; Dompmartin A; Droitcourt C; Gissot V; Goga D; Guibaud L; Herbreteau D; Le Touze A; Léauté-Labrèze C; Lorette G; Mallet S; Martin L; Mazereeuw-Hautier J; Phan A; Plantin P; Quéré I; Vabres P; Bourgoin H; Giraudeau B; Maruani A;
    Trials; 2019 Dec; 20(1):739. PubMed ID: 31847908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.
    Ozeki M; Nozawa A; Yasue S; Endo S; Asada R; Hashimoto H; Fukao T
    Orphanet J Rare Dis; 2019 Jun; 14(1):141. PubMed ID: 31196128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
    Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
    Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of complex periorbital venolymphatic malformation in a neonate with a combination therapy of sirolimus and prednisolone.
    Kim D; Benjamin L; Wysong A; Hovsepian D; Teng J
    Dermatol Ther; 2015; 28(4):218-21. PubMed ID: 25753853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.
    Marchand A; Caille A; Gissot V; Giraudeau B; Lengelle C; Bourgoin H; Largeau B; Leducq S; Maruani A
    Trials; 2022 Jul; 23(1):557. PubMed ID: 35804404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.
    Hammer J; Seront E; Duez S; Dupont S; Van Damme A; Schmitz S; Hoyoux C; Chopinet C; Clapuyt P; Hammer F; Vikkula M; Boon LM
    Orphanet J Rare Dis; 2018 Oct; 13(1):191. PubMed ID: 30373605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral rapamycin: an alternative in children with complicated vascular abnormalities.
    Gómez Sánchez A; Redondo Sedano JV; Pérez Alonso V; Martí Carrera ME; Baro Fernández M; Palencia Pérez SI; Gallego Herrero MC; Gómez Fraile A; Delgado Muñoz MD
    Cir Pediatr; 2020 Oct; 33(4):183-187. PubMed ID: 33016658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sirolimus in children with lymphatic malformations of the head and neck.
    Wiegand S; Dietz A; Wichmann G
    Eur Arch Otorhinolaryngol; 2022 Aug; 279(8):3801-3810. PubMed ID: 35526176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.
    Rössler J; Baselga E; Davila V; Celis V; Diociaiuti A; El Hachem M; Mestre S; Haeberli D; Prokop A; Hanke C; Loichinger W; Quéré I; Baumgartner I; Niemeyer CM; Kapp FG
    Pediatr Blood Cancer; 2021 Aug; 68(8):e28936. PubMed ID: 33580918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus.
    Durand R; Reid JR; Belasco JB; Shellikeri S; Calle-Toro JS; Cahill AM; Srinivasan A
    AJR Am J Roentgenol; 2021 Sep; 217(3):741-752. PubMed ID: 33405944
    [No Abstract]   [Full Text] [Related]  

  • 20. The Use of Sirolimus for Treatment of Orbital Lymphatic Malformations: A Systematic Review.
    Shoji MK; Shishido S; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2020; 36(3):215-221. PubMed ID: 31990892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.